Provided by Tiger Trade Technology Pte. Ltd.

Telomir Pharmaceuticals

1.16
+0.01000.87%
Post-market: 1.160.00000.00%19:03 EST
Volume:74.38K
Turnover:85.63K
Market Cap:39.88M
PE:-3.16
High:1.18
Open:1.15
Low:1.11
Close:1.15
52wk High:5.40
52wk Low:1.07
Shares:34.38M
Float Shares:15.33M
Volume Ratio:0.45
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3665
EPS(LYR):-0.5597
ROE:-303.19%
ROA:-167.42%
PB:5.71
PE(LYR):-2.07

Loading ...

Company Profile

Company Name:
Telomir Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2021
Employees:
- -
Office Location:
100 SE 2nd Street,Suite 2000 #1009,Miami,Florida,United States
Zip Code:
33131
Fax:
- -
Introduction:
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Directors

Name
Position
Erez Aminov
Chief Executive Officer and Chairman
Edward MacPherson
Director
Matthew Paul Del Giudice
Director
Matthew Pratt Whalen
Director

Shareholders

Name
Position
Erez Aminov
Chief Executive Officer and Chairman
Alan Weichselbaum
Chief Financial Officer